Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
11
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Relapsing-Remitting Multiple Sclerosis
View Full LandscapeTarget Indication
Relapsing-Remitting Multiple Sclerosis
Clinical Trial
NCT01838668Last updated: 1/8/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Dimethyl fumarate Accord
Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMADimethyl fumarate Mylan
Dimethyl fumarate Mylan is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMADimethyl fumarate Neuraxpharm
Dimethyl fumarate Neuraxpharm is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMADimethyl fumarate Accord
Dimethyl fumarate Accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMADimethyl fumarate Teva
Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMADimethyl fumarate Neuraxpharm
Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
View on EMADimethyl fumarate Mylan
Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
View on EMADimethyl fumarate Polpharma
Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
View on EMASkilarence
Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
View on EMATecfidera
Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
View on EMAMultiple Sclerosis
Rheumatoid Arthritis
Depressive Disorder, Major
Immune Thrombocytopenic Purpura
Rheumatoid Arthritis